Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 9:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 1,616 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: MDD Clear all
Completed Phase 3 Interventional

An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression

NCT00250614
View directory record Official record
Conditions
Depressive Disorder
Interventions
Saredutant succinate (SR48968C)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 64 Years
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 9, 2010 · Synced Oct 29, 2026, 9:51 AM EDT
Completed Phase 3 Interventional

Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

NCT06029426
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
NMRA-335140, Placebo
Drug
Lead sponsor
Neumora Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
64
States / cities
Huntsville, Alabama • Phoenix, Arizona • Bentonville, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 29, 2026, 9:51 AM EDT
Completed Not applicable Interventional

ON/OFF Stimulation and Reward Motivation in Patients With Deep Brain Stimulators

NCT01590862
View directory record Official record
Conditions
Obsessive Compulsive Disorder, Major Depressive Disorder, Epilepsy
Interventions
Deep Brain Stimulator
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 29, 2026, 9:51 AM EDT
Completed No phase listed Observational

Phenotype Depression Study

NCT01426997
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
21 Years to 65 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Oct 29, 2026, 9:51 AM EDT
Terminated Not applicable Interventional Results available

Cysteamine Therapy for Major Depressive Disorder

NCT00715559
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
cysteamine bitartrate
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 29, 2026, 9:51 AM EDT
Completed Phase 3 Interventional Results available

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)

NCT02932943
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Rapastinel, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
31
States / cities
Beverly Hills, California • Costa Mesa, California • Encino, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2019 · Synced Oct 29, 2026, 9:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

MRI Studies of Emotion in Depression

NCT02429011
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 70 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 29, 2026, 9:51 AM EDT
Completed No phase listed Observational

Testing the Value of Smartphone Assessments of People With Mood Disorders

NCT03429361
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar Disorder
Interventions
Health by Mindstrong
Other
Lead sponsor
Mindstrong
Industry
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Timeline
2017 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2019 · Synced Oct 29, 2026, 9:51 AM EDT
Completed Phase 3 Interventional Results available

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant

NCT04533529
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
51
States / cities
Anaheim, California • Cerritos, California • Irvine, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 29, 2026, 9:51 AM EDT
Completed Phase 3 Interventional Results available

Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

NCT01838681
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Brexpiprazole, ADT
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,986 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
8
States / cities
Little Rock, Arkansas • Cerritos, California • Temecula, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 29, 2026, 9:51 AM EDT
Withdrawn Not applicable Interventional

Accelerated Intermittent Theta-Burst Stimulation for Opiate Use Disorder

NCT03804619
View directory record Official record
Conditions
Opiate Dependence, Suicidal Ideation, Depression, Opioid Use, Opioid-Related Disorders, Opioid-use Disorder, Major Depressive Disorder
Interventions
Accelerated intermittent theta-burst stimulation (aiTBS)
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 29, 2026, 9:51 AM EDT
Completed Phase 3 Interventional

A Fifty-two-week Study to Evaluate the Safety of Saredutant in Adult and Elderly Patients With Depression

NCT00250653
View directory record Official record
Conditions
Depressive Disorder
Interventions
Saredutant succinate (SR48968C)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 29, 2026, 9:51 AM EDT
Completed Not applicable Interventional

Study of Technology-assisted Treatment of Adolescent Depression

NCT01582581
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Telephonic CBT, Wait List Control
Behavioral
Lead sponsor
iHope Network, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Farmington, Connecticut • Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 29, 2026, 9:51 AM EDT
Active, not recruiting Phase 3 Interventional

Psilocybin for Major Depressive Disorder (MDD)

NCT06308653
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Psilocybin 25 mg, Inactive Placebo, Psilocybin 5 mg, Psychosocial Support
Drug · Behavioral
Lead sponsor
Usona Institute
Other
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
29
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 29, 2026, 9:51 AM EDT
Terminated Phase 2 Interventional Results available

The UTHealth Ketamine Project

NCT02882711
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder, Bipolar Disorder
Interventions
Ketamine
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 29, 2026, 9:51 AM EDT
Recruiting Phase 3 Interventional

Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

NCT05850689
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Lumateperone, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
25
States / cities
Huntsville, Alabama • Pico Rivera, California • Farmington, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 29, 2026, 9:51 AM EDT
Completed Not applicable Interventional

Life Improvement Following Traumatic Brain Injury

NCT00878150
View directory record Official record
Conditions
Traumatic Brain Injury, Depression
Interventions
In-person Cognitive Behavioral Therapy, Telephone Cognitive Behavioral Therapy
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 18, 2013 · Synced Oct 29, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder

NCT05376150
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
XEN1101 10 mg, XEN1101 20 mg, Placebo
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
20
States / cities
Anaheim, California • Lafayette, California • Pico Rivera, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 29, 2026, 9:51 AM EDT
Completed Not applicable Interventional

Cognitive Deficits in Major Depressive Disorder and Bipolar Disorder, Depressed Type: Prevalence and Improvement With Treatment of Depressive Symptoms

NCT00844974
View directory record Official record
Conditions
Major Depression, Bipolar Disorder
Interventions
Prevalence
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 29, 2026, 9:51 AM EDT
Completed Not applicable Interventional Results available

The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness.

NCT00466323
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Major Depression
Interventions
Family Member Provider Outreach, Enhanced treatment as usual (e-TAU)
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 70 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
West Los Angeles, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Oct 29, 2026, 9:51 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms

NCT01919216
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Citalopram
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
24 Years to 75 Years · Female only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 29, 2026, 9:51 AM EDT
Completed Phase 3 Interventional Results available

The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder

NCT00107120
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
12 Years to 17 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
28
States / cities
Sacramento, California • San Diego, California • Washington D.C., District of Columbia + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2012 · Synced Oct 29, 2026, 9:51 AM EDT
Completed Phase 2 Interventional

ALTO-100 in MDD and/or PTSD

NCT05117632
View directory record Official record
Conditions
Major Depressive Disorder, Post Traumatic Stress Disorder
Interventions
ALTO-100 PO tablet
Drug
Lead sponsor
Alto Neuroscience
Industry
Eligibility
18 Years to 69 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
23
States / cities
Tempe, Arizona • Little Rock, Arkansas • Costa Mesa, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 29, 2026, 9:51 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers

NCT04618263
View directory record Official record
Conditions
Major Depressive Disorder, Excessive Sleepiness
Interventions
GATE-101
Drug
Lead sponsor
Syndeio Biosciences, Inc
Industry
Eligibility
18 Years to 40 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 29, 2026, 9:51 AM EDT